01—Abstract
A summary of this filing is not available yet.
02—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2026, United Therapeutics kept $0.31.
- Revenue$832.5M100.0%
- Cost of revenue−$99.1M11.9%
- Gross profit$733.4M88.1%
- Operating costs−$425.6M51.1%
- Operating income$307.8M37.0%
- Interest, other & tax−$49.2M5.9%
- Net income$258.6M31.1%
Computed from 10-QQ3 FY2026filed November 4, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue
03—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed November 4, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $832.50M$799.50M | +4.1% |
| Cost of Revenue | $99.10M$100.90M | −1.8% |
| Gross Profit | $733.40M$698.60M | +5.0% |
| R&D Expenses | $279.20M$127.50M | +119.0% |
| SG&A Expenses | $146.40M$182.60M | −19.8% |
| Operating Expenses | $524.70M$411.00M | +27.7% |
| Operating Income | $307.80M$388.50M | −20.8% |
| Net Income | $258.60M$338.70M | −23.6% |
| EPS (Basic) | $6.06$7.73 | −21.6% |
| EPS (Diluted) | $5.71$7.16 | −20.3% |
| Shares Outstanding (Basic) | 42.70M43.80M | −2.5% |
| Shares Outstanding (Diluted) | 45.30M47.30M | −4.2% |
04—Continue